Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ: VERV )

6.150 -0.270 (-4.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Crude Oil Surges Over 1%; US Factory Orders Increase In February
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
The company is now pausing enrollment in the study of its lead asset, VERVE-101. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Verve Therapeutics: Q4 Earnings Insights
Via Benzinga
Verve Therapeutics Announces Updates on its PCSK9 Program
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts. 
Via InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
It's less scary to take on risky investments when the market is rising. 
Via The Motley Fool
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Verve Therapeutics
Via GlobeNewswire
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example. 
Via InvestorPlace
Why Beam Therapeutics Stock Zoomed 17% Higher Today
JPMorgan Chase becomes the latest institution in the company's bull pen. 
Via The Motley Fool
7 Mighty Healthcare Stocks Changing the Game of Medicine
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks. 
Via InvestorPlace
3 Stocks to Buy in the Booming Field of Gene Editing
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
Curing rare inherited illnesses could be a lucrative business model. 
Via The Motley Fool
$18M Bet On Verve Therapeutics? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
Why Verve Therapeutics Stock (VERV) Is Falling
Verve Therapeutics Inc (NASDAQ: VERV) shares are trading lower by 6.3% to $11.18 Wednesday morning after the company priced its proposed public offering of common stock and  
Via Benzinga
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.